Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Pemetrexed in Resectable Non-Small-Cell Lung Cancer (NSCLC) With Pharmacogenomic Correlates.
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 20 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Sep 2010 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 12 Dec 2006 Status change